• This record comes from PubMed

Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort

. 2019 Sep ; 10 (9) : e00071.

Language English Country United States Media print

Document type Journal Article

Persistent link   https://www.medvik.cz/link/pmid31478957

OBJECTIVES: Data on long-term natural history of microscopic colitis (MC), including collagenous (CC) and lymphocytic colitis (LC), are lacking. METHODS: All new cases of MC diagnosed in the Somme area, France, between January 1, 2005, and December 31, 2007, were prospectively included. Colonic biopsies from all patients were reviewed by a group of 4 gastrointestinal pathologist experts to assess the diagnosis of CC or LC. Demographic and clinical data were retrospectively collected from diagnosis to February 28, 2017. RESULTS: One hundred thirty cases of MC, 87 CC and 43 LC, were included (median age at diagnosis: 70 [interquartile range, 61-77] and 48 [IQR, 40-61] years, respectively). The median follow-up was 9.6 years (7.6; 10.6). By the end of the follow-up, 37 patients (28%) relapsed after a median time of 3.9 years (1.2; 5.0) since diagnosis, without significant difference between CC and LC (30% vs 26%; P = 0.47). Twenty patients (15%) were hospitalized for a disease flare, and 32 patients (25%) presented another autoimmune disease. Budesonide was the most widely used treatment (n = 74, 59%), followed by 5-aminosalicylic acid (n = 31, 25%). The median duration of budesonide treatment was 92 days (70; 168), and no adverse event to budesonide was reported. Sixteen patients (22%) developed steroid dependency and 4 (5%) were corticoresistant. No difference in the risk of digestive and extradigestive cancer was observed compared with the general population. None of the death (n = 25) observed during the follow-up were linked to MC. In multivariate analysis, age at diagnosis (HR, 1.03; 95% confidence interval, 1.00-1.06; P = 0.02) and budesonide exposure (HR, 2.50; 95% confidence interval, 1.11-5.55; P = 0.03) were significantly associated with relapse. DISCUSSION: This population-based study showed that after diagnosis, two-third of the patients with MC observed long-term clinical remission. Age at diagnosis and budesonide exposure were associated with a risk of relapse.

See more in PubMed

Lindström CG. “Collagenous colitis” with watery diarrhoea—A new entity? Pathol Eur 1976;11:87–9. PubMed

Fumery M, Kohut M, Gower-Rousseau C, et al. Incidence, clinical presentation, and associated factors of microscopic colitis in northern France: A population-based study. Dig Dis Sci 2016. PubMed

O'Toole A, Coss A, Holleran G, et al. Microscopic colitis: Clinical characteristics, treatment and outcomes in an Irish population. Int J Colorectal Dis 2014;29:799–803. PubMed

Bjørnbak C, Engel PJH, Nielsen PL, et al. Microscopic colitis: Clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther 2011;34:1225–34. PubMed

Tong J, Zheng Q, Zhang C, et al. Incidence, prevalence, and temporal trends of microscopic colitis: A systematic review and meta-analysis. Am J Gastroenterol 2015;110:265–76. PubMed

Järnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995;109:449–55. PubMed

Austin LL, Dobbins WO. Studies of the rectal mucosa in coeliac sprue: The intraepithelial lymphocyte. Gut 1988;29:200–5. PubMed PMC

Fischer H, Holst E, Karlsson F, et al. Altered microbiota in microscopic colitis. Gut 2015;64:1185–6. PubMed PMC

Fine KD, Do K, Schulte K, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000;95:1974–82. PubMed

Järnerot G, Hertervig E, Grännö C, et al. Familial occurrence of microscopic colitis: A report on five families. Scand J Gastroenterol 2001;36:959–62. PubMed

Roth B, Manjer J, Ohlsson B. Microscopic colitis and reproductive factors related to exposure to estrogens and progesterone. Drug Target Insights 2013;7:53–62. PubMed PMC

Fernandez-Bañares F, Esteve M, Salas A, et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci 2001;46:2231–8. PubMed

Beaugerie L, Pardi DS. Review article: Drug-induced microscopic colitis—Proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005;22:277–84. PubMed

Münch A, Bohr J, Miehlke S, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled, 12-month trial. Gut 2016;65:47–56. PubMed PMC

Chan JL, Tersmette AC, Offerhaus GJ, et al. Cancer risk in collagenous colitis. Inflamm Bowel Dis 1999;5:40–3. PubMed

Bonner GF, Petras RE, Cheong DM, et al. Short- and long-term follow-up of treatment for lymphocytic and collagenous colitis. Inflamm Bowel Dis 2000;6:85–91. PubMed

Fernández-Bañares F, Salas A, Esteve M, et al. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol 2003;98:340–7. PubMed

Goff JS, Barnett JL, Pelke T, et al. Collagenous colitis: Histopathology and clinical course. Am J Gastroenterol 1997;92:57–60. PubMed

Gentile NM, Abdalla AA, Khanna S, et al. Outcomes of patients with microscopic colitis treated with corticosteroids: A population-based study. Am J Gastroenterol 2013;108:256–9. PubMed PMC

Sveinsson OA, Orvar KB, Birgisson S, et al. Clinical features of microscopic colitis in a nation-wide follow-up study in Iceland. Scand J Gastroenterol 2008;43:955–60. PubMed

Fernández-Bañares F, de Sousa MR, Salas A, et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis 2013;19:1470–6. PubMed

Schneider S, Rampal A, Hebuterne X, et al. Microscopic colitis. Gastroenterol Clin Biol 1998;22:431–41. PubMed

Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 1994;35:1433–8. PubMed PMC

Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: A retrospective clinical study of 199 Swedish patients. Gut 2004;53:536–41. PubMed PMC

Pardi DS, Ramnath VR, Loftus EV, et al. Lymphocytic colitis: Clinical features, treatment, and outcomes. Am J Gastroenterol 2002;97:2829–33. PubMed

Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7–17. PubMed

Tontini GE, Pastorelli L, Spina L, et al. Microscopic colitis and colorectal neoplastic lesion rate in chronic nonbloody diarrhea: A prospective, multicenter study. Inflamm Bowel Dis 2014;20:882–91. PubMed

Yen EF, Pokhrel B, Bianchi LK, et al. Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. Dig Dis Sci 2012;57:161–9. PubMed

Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: A randomized double-blind placebo-controlled study. Gastroenterology 2009;136:2092–100. PubMed

Miehlke S, Madisch A, Kupcinskas L, et al. Double-blind, double-dummy, randomized, placebo-controlled, multicenter trial of budesonide and mesalamine in collagenous colitis. Gastroenterology 2012;142:S-211.

Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255–60. PubMed

Miehlke S, Hansen JB, Madisch A, et al. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. Inflamm Bowel Dis 2013;19:2763–7. PubMed

Abboud R, Pardi DS, Tremaine WJ, et al. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: A prospective study. Inflamm Bowel Dis 2013;19:550–3. PubMed

Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007;13:175–81. PubMed

Find record

Citation metrics

Archiving options